FDA Advisors Approve Experimental Alzheimer’s Med

The New York Times reports:

A committee of independent advisers to the FDA voted unanimously on Monday that the benefits outweigh the risks of the newest experimental drug for Alzheimer’s disease. Alzheimer’s afflicts more than six million Americans. It has no cure, and there is no treatment or lifestyle modification that can restore memory loss or reverse cognitive decline.

The drug, made by Eli Lilly, is donanemab. It modestly slowed cognitive decline in patients in the early stages of the disease but also had significant safety risks, including swelling and bleeding in the brain. The committee concluded, though, that the consequences of Alzheimer’s are so dire that even a modest benefit can be worthwhile.

Read the full article.

“This is an important development for patients… but I think we’re in the early innings when it comes to treating Alzheimer’s,” says Fmr. FDA Commissioner @ScottGottliebMD on news that FDA advisers say $LLY‘s Alzheimer’s drug is effective and its benefits outweigh the risks. pic.twitter.com/XxZEqNz7wY

— CNBCOvertime (@CNBCOvertime) June 10, 2024